John Fesko, President and Chief Business Officer of Natera Inc . (NASDAQ:NTRA), recently sold 929 shares of the company's common stock. The shares were sold on October 28 at an average price of $118.21, totaling approximately $109,817. Following the transaction, Fesko holds 113,136 shares directly.
This sale was conducted to meet tax withholding obligations related to the vesting of restricted stock units (RSUs), as outlined in a pre-established trading plan compliant with Rule 10b5-1.
In other recent news, Natera, a leader in personalized genetic testing and diagnostics, has been a focal point for several analyst firms. Canaccord Genuity raised Natera's stock price target to $150 from $145, maintaining a Buy rating. The firm highlighted potential updates to reimbursement and guidelines that may favor Natera's products like Panorama and Signatera.
Additionally, Piper Sandler reaffirmed a positive stance on Natera, maintaining an Overweight rating and a price target of $150.00, in anticipation of the new Galaxy study results. TD Cowen also maintained a Buy rating on Natera shares, with a consistent price target of $145.00, as Natera presented nine abstracts at the European Society for Medical Oncology (ESMO) 2024 conference.
Natera has secured a permanent injunction against NeoGenomics (NASDAQ:NEO)' RaDaR assay, asserting its patent rights in the genetic testing market. The company also reported a 12% sequential revenue increase from the first quarter and a 58% year-over-year increase. These recent developments underscore Natera's commitment to growth and innovation in the personalized genetic testing and diagnostics space.
InvestingPro Insights
While John Fesko's recent stock sale was primarily for tax purposes, it's worth examining Natera Inc.'s (NASDAQ:NTRA) current market position and financial performance to provide context for investors.
According to InvestingPro data, Natera's market capitalization stands at $15.65 billion, reflecting its significant presence in the biotechnology sector. The company has demonstrated impressive revenue growth, with a 46.13% increase over the last twelve months as of Q2 2024, reaching $1.36 billion. This strong performance is further emphasized by a remarkable 58.13% quarterly revenue growth in Q2 2024.
InvestingPro Tips highlight that Natera's stock has shown a high return over the last year, with a one-year price total return of 221.08% as of the latest data. The stock is also trading near its 52-week high, currently at 94.9% of that peak, indicating strong investor confidence.
However, it's important to note that Natera is not yet profitable, with a negative operating income of $313.73 million over the last twelve months. This aligns with an InvestingPro Tip suggesting that analysts do not anticipate the company to be profitable this year.
For investors seeking a more comprehensive analysis, InvestingPro offers 12 additional tips for Natera, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.